# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13G**

**Under the Securities Exchange Act of 1934** (Amendment No. 2)\*

# Harvard Bioscience, Inc.

(Name of Issuer)

**Common Stock** (Title of Class of Securities)

> 416906105 (CUSIP Number)

**December 31, 2015** (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☑ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d) \* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

USIP NO. 416906105	Schedule 13G	<u>Page 2 of 6</u>
--------------------	--------------	--------------------

-				
1	NAMES OF REPORTING PERSONS			
	Granahan Investment Management, Inc.			
2			ROPRIATE BOX IF A MEMBER OF A GROUP*	
	(a) □ (	b) □		
	6767767			
3	SEC USE O	NLY		
4	CITIZENCE	IID OD I	PLACE OF ORGANIZATION	
4	CITIZENSE	IIP OK I	PLACE OF ORGANIZATION	
	Massachus	setts		
	iviassaciia	5	SOLE VOTING POWER	
		J		
NU	JMBER OF		334,722	
	SHARES	6	SHARED VOTING POWER	
	IEFICIALLY			
0	WNED BY EACH		0	
RI	EPORTING	7	SOLE DISPOSITIVE POWER	
	PERSON		4.440.545	
	WITH:		1,413,215	
		8	SHARED DISPOSITIVE POWER	
			0	
9	ACCRECA"	ΓΕ ΔΜΟ	UUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
,	MOGREOM	11.711110	OUNT BENEFICINEET OWNED BY ENGINEET ON THE PERSON	
	1,413,215			
10			GGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □	
11	PERCENT (	OF CLA	SS REPRESENTED BY AMOUNT IN ROW 9	
	41)			
	4.2%(1)			
12	TYPE OF R	EPORT1	ING PERSON	
	ΤΔ			

<sup>(1)</sup> Reflects 33,944,207 shares of common stock outstanding as of October 31, 2015, as reported by Harvard Bioscience, Inc. in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2015.

CUSIP NC	5.410900105 Schedule 13G
Item 1(a).	Name of Issuer:
	Harvard Bioscience, Inc.
Item 1(b).	Address of Issuer's Principal Executive Offices:
	84 October Hill Road Holliston, MA 01746
Item 2(a).	Name of Person Filing:
	Granahan Investment Management, Inc.
Item 2(b).	Address of Principal Business Office or, if None, Residence:
	404 Wyman Street, Suite 460 Waltham, MA 02451
Item 2(c).	<u>Citizenship:</u>
	Massachusetts
Item 2(d).	<u>Title of Class of Securities:</u>
	Common Stock, \$0.01 par value per share
Item 2(e).	CUSIP No.:
	416906105
Item 3.	If This Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
(a)	☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 780);
(b)	$\square$ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	$\square$ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	□ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	☑ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)  $\Box$  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

CUSIP NO. 416906105	Schedule 13G	Page 4 of 6
CUSIP NO. 416906105	Schedule 13G	<u>Page 4 of 6</u>

(g) □	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h) 🗆	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) 🗆	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) 🗆	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k) □	Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

#### Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 1,413,215
- (b) Percent of class: 4.2%
- (c) Number of shares as to which the person has:
  - (i) sole power to vote or to direct the vote: 334,722
  - (ii) shared power to vote or to direct the vote: 0
  - (iii) sole power to dispose or to direct the disposition of: 1,413,215
  - (iv) shared power to dispose or to direct the disposition of: 0

## Item 5. Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  $\boxtimes$ .

Item 6. Ownership of More than 5 Percent on Behalf of Another Person

Not Applicable

Item 7. <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control</u>

<u>Person</u>

Not Applicable

Item 8. <u>Identification and Classification of Members of the Group</u>

Not Applicable

Item 9. <u>Notice of Dissolution of Group</u>

Not Applicable

Item 10. <u>Certifications</u>

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 10, 2016

# GRANAHAN INVESTMENT MANAGEMENT, INC.

By: /s/ Jane M. White

Jane M. White, President and CEO

Name/Title